NEW YORK, May 16, 2017 /PRNewswire/ --
On Monday, May 15, 2017, the NASDAQ Composite ended the trading session at 6,149.67, up 0.46%; the Dow Jones Industrial Average edged 0.41% higher, to finish at 20,981.94; and the S&P 500 closed at 2,402.32, marginally advancing 0.48%. Gains were broad based as all the nine sectors ended the day in positive. This Tuesday, Stock-Callers.com has initiated reports coverage on the following Biotechnology equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Biogen Inc. (NASDAQ: BIIB), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Concordia International Corp. (NASDAQ: CXRX). Learn more about these stocks by downloading their free research reports in PDF format at:
On Monday, shares in Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc. recorded a trading volume of 810,654 shares. The stock ended the day at $5.84, declining 0.17% from the last trading session. The Company's shares are trading above their 200-day moving average by 1.35%. Furthermore, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have a Relative Strength Index (RSI) of 37.49. Sign up and read the free research report on BCRX at:
Cambridge, Massachusetts headquartered Biogen Inc.'s stock rose 1.45%, finishing yesterday's session at $258.53. A total volume of 1.65 million shares was traded, which was above their three months average volume of 1.60 million shares. The Company's shares are trading below their 50-day moving average by 6.05%. Additionally, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide, have an RSI of 36.33. The complimentary research report on BIIB can be downloaded at:
Shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc. ended the session 1.27% higher at $3.19. The stock recorded a trading volume of 1.37 million shares. The Company's shares are trading 4.34% below their 50-day moving average. Moreover, shares of Celldex Therapeutics, which focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics, have an RSI of 46.46. Register for free on Stock-Callers.com and access the latest report on CLDX at:
At the closing bell on Monday, Oakville, Canada headquartered Concordia International Corp.'s stock dropped 3.97%, finishing at $1.45. A total volume of 242,859 shares was traded. The Company's shares have gained 8.21% in the last month. The stock is trading 9.98% below its 50-day moving average. Additionally, shares of Concordia International, which owns a portfolio of branded and generic prescription products in the US and internationally, have an RSI of 47.19. Get free access to your research report on CXRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA